by Denise Purdie Andrews | Jul 31, 2023 | Drug Classes
By Kevin Shanks, M.S., D-ABFT-FT As mentioned in the previous post, novel psychoactive substances (NPS) come in different flavors – and opioids, cannabinoids, stimulants, hallucinogens, and benzodiazepines are just a few of them. The Novel Emerging Compounds (NEC)...
by Denise Purdie Andrews | Jul 13, 2023 | Drug Classes
By Kevin Shanks, M.S., D-ABFT-FT Novel psychoactive substances (NPS) come in different varieties – opioids, cannabinoids, stimulants, hallucinogens, and benzodiazepines are just a few of the families on the illicit drug market. Axis developed the Novel Emerging...
by Denise Purdie Andrews | Jul 7, 2023 | Announcements, Drug Classes
Dear Valued Client, In the spirit of continuous improvement, to provide the most relevant panels and tests in the industry, our products are periodically updated to provide new and relevant offerings. It is with that goal in mind that we announce an update to our...
by Denise Purdie Andrews | Jun 6, 2023 | Drug Classes
By Stuart Kurtz, D-ABFT-FT In April, I spoke at the Midwest Association of Toxicology and Therapeutic Drug Monitoring (MATT) annual conference in Columbus, OH. The title of the talk was “Detection of Xylazine in Postmortem Specimens With Fentanyl, Morphine,...
by Denise Purdie Andrews | May 18, 2023 | Drug Classes
By Stuart Kurtz, M.S. D-ABFT-FT As discussed in the previous blog post, vitreous humor has many caveats when interpreting its results in the context of postmortem toxicology. For those considerations and some background on vitreous humor, check out that post first...
